Intra-articular therapy with tumor necrosis factor-α antagonists: an update

Submitted: 27 September 2013
Accepted: 10 February 2014
Published: 14 March 2014
Abstract Views: 2336
PDF: 1108
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

The aim of the study was to review from the present literature the intra-articular (IA) use of the TNF-blocking drugs. A total of 28 papers about this topic were found through a search in PubMed; the first publication’s date was July 2003. These studies include a total of 214 patients affected by 12 different joint diseases that reported a total of 1046 intra-articular therapies carried out in 10 different joint sites. Infliximab and etanercept were the most widely used medications. The safety of this treatment clearly emerges from our analysis, while more difficult was the evaluation of its efficacy. Nevertheless we deduced an ideal patient profile that may better respond to the IA anti-TNF treatment.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Supporting Agencies

none
S. Bello, Rheumatology Unit, Policlinico Hospital, University of Bari
Già borsista,attualmente collaboratore esterno con finalità di ricerca,presso ambulatorio dedicato alle terapie biologiche,

How to Cite

Bello, S., Bonali, C., Serafino, L., Rotondo, C., Terlizzi, N., & Lapadula, G. (2014). Intra-articular therapy with tumor necrosis factor-α antagonists: an update. Reumatismo, 65(6), 257–263. https://doi.org/10.4081/reumatismo.2013.721